Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 16/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3738382 | 0.90 | FFAR1 (0.39) | PDE4AFFAR1KCNH2ADRB2ADRB1 | |
| SCHEMBL3740262 | 0.89 | PDE4A (0.41) | PDE4AADRB2ADRB1ADRB3SMN1; SMN2 | |
| SCHEMBL3740264 | 0.89 | PDE4A (0.41) | PDE4AADRB2ADRB1ADRB3SMN1; SMN2 | |
| SCHEMBL3729936 | 0.89 | PDE4A (0.41) | PDE4AADRB2ADRB1ADRB3SMN1; SMN2 | |
| SCHEMBL3729934 | 0.89 | PDE4A (0.41) | PDE4AADRB2ADRB1ADRB3SMN1; SMN2 | |
| SCHEMBL3728384 | 0.88 | ADRB3 (0.44) | PDE4AFFAR1ADRB2ADRB1ADRB3 | |
| SCHEMBL3728385 | 0.88 | ADRB3 (0.44) | PDE4AFFAR1ADRB2ADRB1ADRB3 | |
| SCHEMBL3740910 | 0.88 | ADRB3 (0.44) | PDE4AFFAR1ADRB2ADRB1ADRB3 | |
| SCHEMBL3740911 | 0.88 | ADRB3 (0.44) | PDE4AFFAR1ADRB2ADRB1ADRB3 | |
| SCHEMBL3743304 | 0.85 | PDE4A (0.39) | PDE4AADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114867-B1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-7829563-B2 | Aminoamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829563-B2 | Aminoamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829563-B2 | Aminoamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HCRTR1, HCRTR2, HRH3 | PDE4A 2570/4885FFAR1 189/4885KCNH2 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.